Skip to content
2000
Volume 2, Issue 2
  • ISSN: 1567-2050
  • E-ISSN: 1875-5828

Abstract

Blocking the effects of fractalkine therapeutically may regulate microglia cell activation and provide neuroprotection in the AD brain. A human herpesvirus 8-encoded chemokine, termed vMIP-II is a non-selective chemokine receptor antagonist (binding multiple chemokine receptors, including CX3CR1). By comparing vMIP-II and FKN, we have generated molecules that selectively antagonize CX3CR1 activation. The results from these studies will guide future development of therapeutic agents designed to modulate microglial activation with the goal of preventing or slowing the progression of AD.

Loading

Article metrics loading...

/content/journals/car/10.2174/1567205053585765
2005-04-01
2024-11-24
Loading full text...

Full text loading...

/content/journals/car/10.2174/1567205053585765
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test